ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,941 to 3,960 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
17P (Hydroxyprogesterone Caproate Injection) vs Vehicle: Fetal/Early Infant Death19 of 1,130

11 of 578

-0.2 points

-1.8 to 1.0

1,708NCT01004029

Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery

17P (Hydroxyprogesterone Caproate Injection) vs Vehicle: Preterm Birth Prior to 37 Weeks Gestation257 of 1,130

125 of 578

1.1 points

-3.1 to 5.2

1,708NCT01004029

Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery

17P (Hydroxyprogesterone Caproate Injection) vs Vehicle: Preterm Birth Prior to 32 Weeks Gestation54 of 1,130

30 of 578

-0.4 points

-2.8 to 1.7

1,708NCT01004029

Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery

Pooled 20vPnC vs 13vPnC: serious adverse events10 of 1,463

0 of 245

0.7 points

-0.9 to 1.3

1,708NCT03828617

Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

17P (Hydroxyprogesterone Caproate Injection) vs Vehicle: serious adverse events34 of 1,128

18 of 578

-0.1 points

-2.0 to 1.5

1,706NCT01004029

Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery

ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants With Non Fatal Myocardial Infarction35 of 877

37 of 828

-0.5 points

-2.4 to 1.5

1,705NCT01499511

Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study

Pre-intervention Group vs Intervention Group: Number of Patients That Die During the Hospitalization338 of 1,192

105 of 513

7.9 points

3.4 to 12.1

1,705NCT02543554

ED Lung Protective Ventilation to Reduce Complications

Pre-intervention Group vs Intervention Group: Number of Patients That Experience Pulmonary Complications After Admission From the Emergency Department171 of 1,192

38 of 513

6.9 points

3.7 to 9.8

1,705NCT02543554

ED Lung Protective Ventilation to Reduce Complications

Arm 1: VAQTA™ vs Arm 2: VAQTA™ +ProQuad™: Participants With Elevated Temperature (>=102.2F/39.0C)56 of 1,383

13 of 320

-0.0 points

-2.9 to 2.0

1,703NCT00326183

Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)

Normal Saline vs Magnesium Sulfate: Modified Rankin Score ≤2445 of 843

449 of 857

0.4 points

-4.3 to 5.1

1,700NCT00059332

Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial

Normal Saline vs Magnesium Sulfate: Mortality131 of 843

132 of 857

0.1 points

-3.3 to 3.6

1,700NCT00059332

Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial

Normal Saline vs Magnesium Sulfate: Symptomatic Intracranial Hemorrhage28 of 843

18 of 857

1.2 points

-0.3 to 2.9

1,700NCT00059332

Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial

Normal Saline vs Magnesium Sulfate: Serious Adverse Events422 of 843

439 of 857

-1.2 points

-5.9 to 3.6

1,700NCT00059332

Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial

Normal Saline vs Magnesium Sulfate: Modified Rankin Score of 0 or 1311 of 843

313 of 857

0.4 points

-4.2 to 4.9

1,700NCT00059332

Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial

Normal Saline vs Magnesium Sulfate: serious adverse events422 of 843

439 of 857

-1.2 points

-5.9 to 3.6

1,700NCT00059332

Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial

With Suicidal Ideation (Including Suicide Attempt) vs Without Suicidal Ideation (Including Suicide Attempt): Factors Considered to Affect the Efficacy of Sertraline: Suicidal Ideation (Including Suicide Attempt)319 of 397

1,136 of 1,303

-6.8 points

-11.4 to -2.7

1,700NCT00605865

Drug Use Investigation of Jzoloft.

ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants Who Have Required Renal Replacement Therapy (Dialysis or Kidney Transplant) Since the End of the ASCOT Trial10 of 874

9 of 826

0.1 points

-1.0 to 1.1

1,700NCT01499511

Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study

ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants With Non Fatal Stroke/TIA (Transient Ischaemic Attack)29 of 877

52 of 823

-3.0 points

-5.1 to -1.0

1,700NCT01499511

Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study

Bexagliflozin Tablets, 20 mg vs Placebo Tablets: deaths from any cause39 of 1,132

26 of 567

-1.1 points

-3.4 to 0.8

1,699NCT02558296

Bexagliflozin Efficacy and Safety Trial

Bexagliflozin Tablets, 20 mg vs Placebo Tablets: serious adverse events373 of 1,132

208 of 567

-3.7 points

-8.6 to 1.0

1,699NCT02558296

Bexagliflozin Efficacy and Safety Trial

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=198"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=198

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01004029-7fed5651",
        "title": "17P (Hydroxyprogesterone Caproate Injection) vs Vehicle: Fetal/Early Infant Death",
        "summary": "19 of 1130 against 11 of 578; risk difference -0.2 points, 95% interval -1.8 to 1.0; NCT01004029, Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery",
        "record": "/library/comparisons/NCT01004029-7fed5651",
        "nct_id": "NCT01004029",
        "kind": "outcome",
        "participants": 1708,
        "risk_difference": {
          "value": -0.002216982576476713,
          "lower": -0.01812443077334891,
          "upper": 0.01029454516455793
        },
        "group_1": "19 of 1,130",
        "group_2": "11 of 578",
        "difference": "-0.2 points",
        "interval": "-1.8 to 1.0",
        "trial_title": "Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery"
      },
      {
        "id": "NCT01004029-b040dc89",
        "title": "17P (Hydroxyprogesterone Caproate Injection) vs Vehicle: Preterm Birth Prior to 37 Weeks Gestation",
        "summary": "257 of 1130 against 125 of 578; risk difference 1.1 points, 95% interval -3.1 to 5.2; NCT01004029, Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery",
        "record": "/library/comparisons/NCT01004029-b040dc89",
        "nct_id": "NCT01004029",
        "kind": "outcome",
        "participants": 1708,
        "risk_difference": {
          "value": 0.011170652540037351,
          "lower": -0.03129687657286433,
          "upper": 0.05169996060033175
        },
        "group_1": "257 of 1,130",
        "group_2": "125 of 578",
        "difference": "1.1 points",
        "interval": "-3.1 to 5.2",
        "trial_title": "Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=199",
  "request_id": "evbRV8oCTHXmVWOf"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?